169 related articles for article (PubMed ID: 36958427)
1. Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness.
Sharif NA
Exp Eye Res; 2023 Jul; 232():109444. PubMed ID: 36958427
[TBL] [Abstract][Full Text] [Related]
2. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
Sharif NA
Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
[TBL] [Abstract][Full Text] [Related]
3. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.
Gazzard G; Konstantakopoulou E; Garway-Heath D; Garg A; Vickerstaff V; Hunter R; Ambler G; Bunce C; Wormald R; Nathwani N; Barton K; Rubin G; Morris S; Buszewicz M
Health Technol Assess; 2019 Jun; 23(31):1-102. PubMed ID: 31264958
[TBL] [Abstract][Full Text] [Related]
4. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
[TBL] [Abstract][Full Text] [Related]
5. Gene therapies and gene product-based drug candidates for normalizing and preserving tissue functions in animal models of ocular hypertension and glaucoma.
Sharif NA
Mol Aspects Med; 2023 Dec; 94():101218. PubMed ID: 37976898
[TBL] [Abstract][Full Text] [Related]
6. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
[TBL] [Abstract][Full Text] [Related]
7. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
Kass MA; Heuer DK; Higginbotham EJ; Johnson CA; Keltner JL; Miller JP; Parrish RK; Wilson MR; Gordon MO
Arch Ophthalmol; 2002 Jun; 120(6):701-13; discussion 829-30. PubMed ID: 12049574
[TBL] [Abstract][Full Text] [Related]
8. Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty.
Zhang L; Weizer JS; Musch DC
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD010746. PubMed ID: 28231380
[TBL] [Abstract][Full Text] [Related]
9. [Aiming for zero blindness].
Nakazawa T
Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
[TBL] [Abstract][Full Text] [Related]
10. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
[TBL] [Abstract][Full Text] [Related]
11. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.
Sharif NA; Odani-Kawabata N; Lu F; Pinchuk L
Exp Eye Res; 2023 Apr; 229():109415. PubMed ID: 36803996
[TBL] [Abstract][Full Text] [Related]
12. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action.
Sharif NA
Curr Drug Targets; 2010 Aug; 11(8):978-93. PubMed ID: 20426763
[TBL] [Abstract][Full Text] [Related]
13. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
[TBL] [Abstract][Full Text] [Related]
14. Intraocular pressure changes following topical ocular hypotensive medications washout.
Ho H; Daas A; Ho J; Alaghband P; Galvis EA; de Antonio Ramirez A; Grassi P; Lim R; Lim KS
Br J Ophthalmol; 2021 Feb; 105(2):205-209. PubMed ID: 32277009
[TBL] [Abstract][Full Text] [Related]
15. Four years later: a clinical update on latanoprost.
Ravinet E; Mermoud A; Brignoli R
Eur J Ophthalmol; 2003 Mar; 13(2):162-75. PubMed ID: 12696636
[TBL] [Abstract][Full Text] [Related]
16. Long-term evaluation of ocular hypertension with primary angle closure and primary open angles.
Sihota R; Selvan H; Sharma A; Gupta A; Gupta V; Dada T; Upadhyay AD
Int Ophthalmol; 2019 Apr; 39(4):803-812. PubMed ID: 29508190
[TBL] [Abstract][Full Text] [Related]
17. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
[TBL] [Abstract][Full Text] [Related]
18. Laser trabeculoplasty for open-angle glaucoma and ocular hypertension.
Rolim-de-Moura CR; Paranhos A; Loutfi M; Burton D; Wormald R; Evans JR
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD003919. PubMed ID: 35943114
[TBL] [Abstract][Full Text] [Related]
19. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
